IDEXX LABORATORIES INC /DE
Congressional Trades
Whale Activity
- Increased392
- New92
- Held211
- Decreased531
- Closed104
- No prior filing55
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 8.1M | $4.23B | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.2M | $2.69B | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.0M | $2.07B | increased |
| STATE STREET CORP | 3.8M | $1.96B | increased |
| Invesco Ltd. | 3.4M | $1.76B | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 2.6M | $1.37B | increased |
| BAMCO INC /NY/ | 1.8M | $930.8M | decreased |
| MORGAN STANLEY | 1.4M | $717.7M | increased |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.4M | $709.9M | increased |
| GOLDMAN SACHS GROUP INC | 1.2M | $614.4M | increased |
| T. Rowe Price Investment Management, Inc. | 1.0M | $539.8M | increased |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.0M | $539.4M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Underberg Sharon E.EVP, GC & Corporate Secretary | Sale | −6,348 | $688.25 | $4.4M | Nov 4, 2026 | Form 4 ↗ |
| Underberg Sharon E.EVP, GC & Corporate Secretary | Sale | −1,503 | $689.05 | $1.0M | Nov 4, 2026 | Form 4 ↗ |
| Underberg Sharon E.EVP, GC & Corporate Secretary | Sale | −1,055 | $690.02 | $728K | Nov 4, 2026 | Form 4 ↗ |
| MAZELSKY JONATHAN JAYExecutive Chair of the Board · Director | Sale | −840 | $707.00 | $594K | Nov 4, 2026 | Form 4 ↗ |
| MAZELSKY JONATHAN JAYExecutive Chair of the Board · Director | Sale | −775 | $711.31 | $551K | Nov 4, 2026 | Form 4 ↗ |
| MAZELSKY JONATHAN JAYExecutive Chair of the Board · Director | Sale | −4,540 | $701.36 | $3.2M | Nov 4, 2026 | Form 4 ↗ |
| MAZELSKY JONATHAN JAYExecutive Chair of the Board · Director | Sale | −4,075 | $699.33 | $2.8M | Nov 4, 2026 | Form 4 ↗ |
| MAZELSKY JONATHAN JAYExecutive Chair of the Board · Director | Sale | −3,950 | $703.45 | $2.8M | Nov 4, 2026 | Form 4 ↗ |
| MAZELSKY JONATHAN JAYExecutive Chair of the Board · Director | Sale | −331 | $711.95 | $236K | Nov 4, 2026 | Form 4 ↗ |
| MAZELSKY JONATHAN JAYExecutive Chair of the Board · Director | Sale | −240 | $705.59 | $169K | Nov 4, 2026 | Form 4 ↗ |
| MAZELSKY JONATHAN JAYExecutive Chair of the Board · Director | Sale | −2,136 | $702.21 | $1.5M | Nov 4, 2026 | Form 4 ↗ |
| MAZELSKY JONATHAN JAYExecutive Chair of the Board · Director | Sale | −1,945 | $698.26 | $1.4M | Nov 4, 2026 | Form 4 ↗ |
| MAZELSKY JONATHAN JAYExecutive Chair of the Board · Director | Sale | −1,840 | $707.84 | $1.3M | Nov 4, 2026 | Form 4 ↗ |
| MAZELSKY JONATHAN JAYExecutive Chair of the Board · Director | Sale | −1,667 | $700.33 | $1.2M | Nov 4, 2026 | Form 4 ↗ |
| MAZELSKY JONATHAN JAYExecutive Chair of the Board · Director | Sale | −1,501 | $710.12 | $1.1M | Nov 4, 2026 | Form 4 ↗ |
| MAZELSKY JONATHAN JAYExecutive Chair of the Board · Director | Sale | −1,300 | $709.00 | $922K | Nov 4, 2026 | Form 4 ↗ |
| Lane MichaelExecutive Vice President | Sale | −243 | $687.85 | $167K | Nov 4, 2026 | Form 4 ↗ |
| Lane MichaelExecutive Vice President | Sale | −2,059 | $689.70 | $1.4M | Nov 4, 2026 | Form 4 ↗ |
| Lane MichaelExecutive Vice President | Sale | −1,677 | $687.46 | $1.2M | Nov 4, 2026 | Form 4 ↗ |
| JUNIUS DANIEL MDirector · Director | Sale | −700 | $705.78 | $494K | Nov 4, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.5M | $1.32B | 0.06% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 2.0M | $1.08B | 0.06% | Jun 30, 2026 |
| VANGUARD MID-CAP INDEX FUND VANGUARD INDEX FUNDS | 1.7M | $899.8M | 0.40% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 1.7M | $881.5M | 0.18% | Jun 30, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 1.1M | $571.3M | 0.06% | Jun 30, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 1.0M | $570.0M | 0.07% | Aug 31, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 956.2K | $503.4M | 0.06% | Jun 30, 2026 |
| VANGUARD GROWTH INDEX FUND VANGUARD INDEX FUNDS | 942.3K | $496.1M | 0.13% | Jun 30, 2026 |
| Baron Partners Fund BARON SELECT FUNDS | 846.3K | $445.5M | 2.47% | Jun 30, 2026 |
| AMCAP Fund | 732.9K | $408.0M | 0.43% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list IDXX's shares (CUSIP 45168D104), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Vanguard Portfolio ManagementSCHEDULE 13G · passive (13G) · 4.0M shares5.0%
Oct 30, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming IDEXX LABORATORIES INC /DE as the client.
Government Contracts
- Department of Defense8509926115!WATER SAMPLING TEST KIT$326
Jun 1, 2023 · ↗ - Department of Defense8509588903!COMPARATOR,COLOR$12
Dec 14, 2022 · ↗ - Department of Defense8509814633!COMPARATOR,COLOR$12
Apr 6, 2023 · ↗ - Department of Defense8509658334!COMPARATOR,COLOR$12
Jan 24, 2023 · ↗ - Department of Defense8509814622!COMPARATOR,COLOR$12
Apr 6, 2023 · ↗ - Department of Defense8509748540!COMPARATOR,COLOR$47
Mar 8, 2023 · ↗ - Department of Defense8509833519!WATER SAMPLING TEST$315
Apr 14, 2023 · ↗ - Department of Health and Human ServicesDVMAX ANNUAL SUPPORT FEE$15K
Sep 15, 2020 · ↗
U.S. Patents
No USPTO patent applications found for IDEXX LABORATORIES INC /DE.
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.30B | $3.90B | $3.66B | $3.37B | $3.22B |
| Operating income | $1.36B | $1.13B | $1.10B | $898.8M | $932.0M |
| Net income | $1.06B | $887.9M | $845.0M | $679.1M | $744.8M |
| Diluted EPS | $13.08 | $10.67 | $10.06 | $8.03 | $8.60 |
| Operating cash flow | $1.18B | $929.0M | $906.5M | $543.0M | $755.5M |
| Cash and equivalents | $180.1M | $288.3M | $453.9M | $112.5M | $144.5M |
| Total assets | $3.35B | $3.29B | $3.26B | $2.75B | $2.44B |
| Total liabilities | $1.75B | $1.70B | $1.78B | $2.14B | $1.75B |
| Shareholders' equity | $1.61B | $1.60B | $1.48B | $608.7M | $690.0M |
As IDEXX LABORATORIES INC /DE tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 20, 2026 ↗
Stock Splits
- 2-for-1Stock splitJun 16, 2015
- 2-for-1Stock splitNov 27, 2007
- 2-for-1Stock splitJun 6, 1995
- 2-for-1Stock splitOct 4, 1993
Split dates and ratios from the price history · Close Prices from Tiingo.com



